Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Huisheng Biopharma Closes $70 Million Round for Diabetes Drug Portfolio

publication date: Sep 26, 2022

In June, Jilin Huisheng Biopharm completed a $70 million Series A funding to support development of its diabetes therapies. Sihuan Pharma formed Huisheng in 2014 as a non-wholly owned subsidiary to develop products for diabetes and its complications After seven years of development and $210 million of investment, Huisheng has an R&D team of over 200 people and a large portfolio of 40 products at different stages aimed at diabetes. After the A round, Sihuan still owns a 68% stake in Huisheng, while the four A round investors own 10%. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital